Suchergebnisse - "Corso, Alessandro"

PubPharm (6)

1

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics

enthalten in: European journal of haematology | 2022

von Richardson, P. | Schjesvold, F. | Weisel, K. | +25

2

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM) : outcomes by prior treatment at first relapse

enthalten in: Leukemia | 2021

von Dimopoulos, M. | Weisel, K. | Moreau, P. | +17

3

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Richardson, P. | Oriol, A. | Beksac, M. | +123

CommentIn: Lancet Oncol. 2019 Jun;20(6):743-744. - PMID 31097404

4

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

enthalten in: The New England journal of medicine | 2018

von Mateos, M. | Dimopoulos, M. | Cavo, M. | +127

5

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2016

von Palumbo, A. | Chanan-Khan, A. | Weisel, K. | +117

CommentIn: Nat Rev Clin Oncol. 2016 Oct;13(10):592. - PMID 27600254

6

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma : results of a global phase 3b expanded access program

enthalten in: British journal of haematology | 2009

von Mikhael, J. | Belch, A. | Prince, H. | +7

1
[1]